Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Brooklyn ImmunoTherapeutics LLC

Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders
From Brooklyn ImmunoTherapeutics LLC
Via Business Wire
Tickers BTX
Brooklyn ImmunoTherapeutics Reports Inducement Grants
From Brooklyn ImmunoTherapeutics LLC
Via Business Wire
Tickers BTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.